Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.LyondellBasell To Close LDPE Unit At Carrington, UK
LyondellBasell has announced that it will close the low density polyethylene (LDPE) plant located at its Carrington, UK, site by the end of this year. Tassilo Bader, senior
LyondellBasell has announced that it will close the low density polyethylene (LDPE) plant located at its Carrington, UK, site by the end of this year. Tassilo Bader, senior
I-Flow, through its wholly-owned subsidiary AcryMed, has announced the availability of its family of four conveniently sized ON-Q SilverDressings. These thin film dressings contain ionic silver that is
Cepacol has introduced Cepacol Fizzlers, a single symptom sore throat relief product designed specifically for kids. Cepacol Fizzlers provides a solution for parents with children aged 5-12 suffering
Bristol-Myers Squibb has reached an agreement for the sale of its OTC assets in Asia Pacific (excluding China and Japan) to Taisho Pharmaceutical (Taisho). Under the terms of
GENova Biotherapeutics (GENova) has signed a collaboration agreement with Prime BioResearch (Prime BioResearch), the agreement is focused on how personalised medicine can be applied to cure cancer. The
Amgen has announced that the Court of Appeals for the Federal Circuit affirmed the Massachusetts District Court’s decision that Roche’s peg-EPO product, Mircera, infringes four Amgen patents (‘868,
AP Pharma has entered into a license and development agreement with Merial. The license agreement follows a successful research collaboration between the companies. Under the terms of the
Merck Sharp & Dohme (MSD) has reported that Isentress (raltegravir) has been granted an expanded license from the European Union Commission for use in combination with other antiretroviral
Poniard Pharmaceuticals (Poniard) has announced that 320 evaluable events (patient deaths) have occurred in its pivotal phase 3 SPEAR trial. The trial is being conducted in accordance with
Pieris has entered into a collaboration agreement with Allergan that combines Pieris’ proprietary Anticalin technology with Allergan’s expertise in drug delivery and ophthalmic drug development with a goal